Cogent Biosciences Q2 net loss widens on higher expenses

Cogent Biosciences

10/08/2026 13:10

Overview
U.S. biotechnology firm's Q2 net loss widened yr/yr on higher R&D and G&A expenses
Company completed onboarding of commercial and medical teams ahead of potential bezuclastinib launches
Cogent ended Q2 with $792.3 mln in cash, expects runway into late 2028

Outlook
Company expects potential FDA approval of bezuclastinib for GIST by Nov 30, 2026
Company expects potential FDA approval of bezuclastinib for NonAdvSM by Dec 30, 2026
Cogent expects existing cash to fund operations into late 2028

Result Drivers
CLINICAL PROGRAM COSTS - Co said higher R&D expenses were mainly due to costs for SUMMIT, PEAK and APEX trials, regulatory activities, early-stage research and pre-approval manufacturing
COMMERCIAL READINESS - Co said higher G&A expenses reflected investments in personnel and infrastructure to support anticipated bezuclastinib launch and organizational growth

Company press release: ID:nGNX6zHx82

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$96.41 mln
 
Q2 Income from Operations
 
-$102.64 mln
 
Q2 Operating Expenses
 
$102.64 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cogent Biosciences, Inc. is $55.00, about 29.7% above its August 7 closing price of $42.39

Reuters Recommended Reads
Aug 10 - Oruka Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Tonix Q2 revenue rises sharply on TONMYA launch
Aug 7 - bioAffinity Technologies Q2 revenue rises on CyPath Lung demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)